iShares Biotechnology ETF
415 hedge funds and large institutions have $3.86B invested in iShares Biotechnology ETF in 2016 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 130 increasing their positions, 143 reducing their positions, and 75 closing their positions.
9% less repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 143
4% less funds holding
Funds holding: 432 → 415 (-17)
11% less first-time investments, than exits
New positions opened: 67 | Existing positions closed: 75
30% less capital invested
Capital invested by funds: $5.55B → $3.86B (-$1.69B)
32% less call options, than puts
Call options by funds: $608M | Put options by funds: $901M
34% less funds holding in top 10
Funds holding in top 10: 32 → 21 (-11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$136M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$113M |
| 3 |
Jane Street
New York
|
+$67.1M |
| 4 |
Two Sigma Advisers
New York
|
+$52.8M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$182M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$127M |
| 3 |
Goldman Sachs
New York
|
-$120M |
| 4 |
Morgan Stanley
New York
|
-$111M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$95M |
IBB Hedge Fund Activity: Q1 2016 in Review
415 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2016, worth a combined $3.86B — down 30% from $5.55B a quarter earlier.
Sellers outnumbered buyers: 75 funds closed out of IBB and 67 opened new positions — a net loss of 8 holders — while 143 trimmed existing stakes and 130 added.
The largest buyer was Citigroup, adding an estimated $136M. The largest seller was JP Morgan Chase, cutting an estimated $182M.
- 415 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2016, down from 432 in Q4 2015.
- Funds reported $3.86B of iShares Biotechnology ETF stock for Q1 2016, down 30% quarter-over-quarter.
- 67 funds opened new iShares Biotechnology ETF positions in Q1 2016 and 75 closed out, a net change of -8 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2016 was Citigroup, an estimated $136M added.
- The largest iShares Biotechnology ETF seller in Q1 2016 was JP Morgan Chase, an estimated $182M sold.
Based on aggregated 13F filings for Q1 2016.